Medications like Ozempic (aka semaglutide, a medication approved for type 2 diabetes) and Wegovy (also semaglutide, but at a slightly higher dose, and indicated for obesity),  are all over the media, resulting in high demands and even medication shortages.
In response to the high demand, and the limited insurance coverage for these medications, some compounding pharmacies are offering compounded peptides, like semaglutide, and some clinicians are offering these compounded medications to their patients. What are we to make of this? Are these medications safe? Effecive? Legal? How should we approach this tricky subject?
Fortunately, the Obesity Medicine Association has given us guidance on this topic, through their position statememt on compounded peptides. Listen in to get the highlights on the position statement!

For the full article, click HERE

Support the show

The Gaining Health Podcast will release a new episode monthly, every second or third Wednesday of the month. Episodes including interviews with obesity experts as well as scientific updates and new guidelines for the management of obesity.

If you're a clinician or organization looking to start or optimize an obesity management program, and you want additional support and resources, check out the Gaining Health website! We offer a Roadmap to starting an obesity program or practice, pre-recorded Master Classes, digital resources including patient education materials and office forms, and much more!
Check out our resources on our Gaining Health Shop!

If you are loving this podcast, please consider supporting us on Patreon